The Bull Rankings scorecard — our quality-growth score is 42.6 / 100, built from three pillars scored 0–100: Quality 41, Growth 47, Value 39 (valuation is judged against sector peers). At today's price, our reverse-DCF read says the market is implicitly betting on free-cash-flow growth of about 2% a year next year, rising to 4% a year by year ten — a gauge of how much optimism is already in the stock.
The thesis
Gilead’s current price is a discount to a growth story that is already priced in, but the upside remains. The Bull Rankings model gives GILD a 42.6/100 quality‑growth score, with Growth at 47, Quality at 41 and Value at 39. Growth is the strongest pillar, suggesting the market sees a trajectory that can sustain the company’s revenue engine. In other words, the stock is not over‑optimistic; it is priced on a realistic, modest expansion path.
Three figures back this view: $179.5 b market cap on a $144.74 share, a PS TTM of 5.9, and $12.9 b free‑cash‑flow. The price sits near the 52‑week high of 157.29, yet the analyst consensus 1‑year target of 158.65 indicates a modest upside window. These numbers paint a picture of a firm that is still investing heavily but has a clear revenue engine that can keep the cash flow engine running.
What the business actually is
Gilead’s revenue comes from a handful of blockbuster therapies that address unmet needs. In HIV‑1 treatment, Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and Yeztugo dominate the market, while Epclusa, Livdelzi, and Vemlidy serve chronic hepatitis C, primary biliary cholangitis, and chronic hepatitis B. The company also sells Tecartus, a T‑cell therapy for adult patients, Trodelvy, an IV injection, and Yescarta, a CAR‑T cell suspension for adult patients. These products are sold in the United States, Europe, and internationally, targeting specialists and hospitals that treat chronic viral infections and certain cancers. The HIV and hepatitis lines are the revenue engines, with the newer cell‑therapy products adding diversification and higher margins.
Why it can (or can't) keep compounding
Gilead’s moat is built on a patent‑protected portfolio that delivers high‑margin, life‑saving drugs. The company’s ability to bundle therapies—for example, Biktarvy as a single‑pill regimen—creates a competitive advantage that is hard to replicate. The negative profit margin today reflects heavy R&D and marketing spend, but the free‑cash‑flow of $12.9 b shows that the company can sustain its pipeline investments. The debt‑to‑equity of 2.23 is high, yet the low beta indicates that investors view the company as a stable, defensive play. The strongest model signal is the Growth pillar at 47, suggesting that the market believes the company can continue to expand its revenue base, especially as newer therapies like Tecartus and Yescarta mature.
The valuation question
This trajectory is below the trailing revenue growth of 5.5 %, meaning the market is pricing in a pessimistic view of future expansion. The PS TTM of 5.9 and the current price of $144.74 place GILD on the expensive side of its peers, as reflected by the Value score of 39. The analyst consensus 1‑year target of 158.65 is only a 9 % upside, indicating that the market does not expect a dramatic turnaround. In short, the valuation is tight; the upside is modest and hinges on the company’s ability to keep its pipeline alive and its pricing power intact.
The bear case
These figures signal that Gilead is still burning cash and has not yet achieved profitability. If the company fails to launch a new blockbuster or if patent expirations erode its revenue base, the free‑cash‑flow could shrink. A decline in the PS multiplier below 5.9 would further compress the valuation. The current debt‑to‑equity of 2.23 also raises concerns about financial flexibility if cash flows falter.
What would change our mind
- Profitability turns positive: A shift from a -10.6 % margin to a positive margin would dramatically improve the Value score and lift the stock’s appeal.
- Revenue growth accelerates: If the company can push revenue growth above 5.5 % consistently, the reverse‑DCF implied growth would become more optimistic, justifying a higher price.
- Debt reduction: Bringing the debt‑to‑equity ratio below 1.5 would signal stronger balance‑sheet health and could improve the Quality pillar, moving the overall score above 50.
These thresholds are concrete, measurable, and would flip the current thesis from a cautious upside to a more confident stance.